Peptide-based research has opened exciting new avenues in metabolic health, body composition, and age-related medicine. Among the most studied peptides in this field is tesamorelin, a synthetic growth hormone-releasing hormone (GHRH) analog (Wang & Tomlinson). Originally developed and approved for treating HIV-associated lipodystrophy (Stanley et al.), the tesamorelin peptide has gained wider research interest due to its potential effects on fat metabolism (Falutz et al.), muscle preservation (Clemmons et al.), and insulin sensitivity (Falutz et al.).
This article offers a comprehensive overview of tesamorelin’s mechanism, benefits, and potential research applications, helping scientists and clinicians understand its growing relevance in endocrine and metabolic studies.
